Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00460603 · ClinicalTrials.gov registry record · Phase 1
Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 187
- Enrollment target
NCT00460603 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 187 participants.
The verdict
NCT00460603, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 187 participants
- Enrollment target
Study Summary
To determine the safety and efficacy of AG-013736 in combination with other standard of care medication in patients with first line metastatic colorectal cancer.
Interventions
- DRUG bevacizumab
- DRUG AG-013736 (axitinib)
- DRUG AG-013726
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2006-01 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00460603
The ClinicalTrials.gov registry entry for NCT00460603 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 187 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which bevacizumab is the first listed.
NCT00460603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00460603 about?
NCT00460603 is a clinical study titled "Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer". To determine the safety and efficacy of AG-013736 in combination with other standard of care medication in patients with first line metastatic colorectal cancer.
What is the current status of trial NCT00460603?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 187 participants. The study started on 2006-01. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00460603?
The interventions under investigation include: bevacizumab (DRUG), AG-013736 (axitinib) (DRUG), AG-013726 (DRUG).
Who is sponsoring clinical trial NCT00460603?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.